Academic Journal
Ketamine Dose and Duration Effects in Internalizing Disorders.
| Τίτλος: | Ketamine Dose and Duration Effects in Internalizing Disorders. |
|---|---|
| Συγγραφείς: | McNaughton N; Department of Psychology, University of Otago, Dunedin, New Zealand., Beaglehole B; Department of Psychological Medicine, University of Otago, Christchurch, New Zealand., Glue P; Department of Psychological Medicine, University of Otago, Dunedin, New Zealand. |
| Πηγή: | Journal of clinical pharmacology [J Clin Pharmacol] 2026 Sep; Vol. 66 (9), pp. e70299. |
| Τύπος έκδοσης: | Journal Article; Randomized Controlled Trial |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2013- : Oxford : Wiley Original Publication: Stamford, Conn., Hall Associates. |
| Ιατρικοί όροι (MeSH): | Ketamine*/administration & dosage , Ketamine*/therapeutic use , Ketamine*/pharmacokinetics , Stress Disorders, Post-Traumatic*/drug therapy , Obsessive-Compulsive Disorder*/drug therapy , Depressive Disorder, Treatment-Resistant*/drug therapy, Generalized Anxiety Disorder/drug therapy ; Phobia, Social/drug therapy ; Humans ; Double-Blind Method ; Dose-Response Relationship, Drug ; Cross-Over Studies ; Male ; Female ; Adult ; Middle Aged ; Young Adult |
| Περίληψη: | The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0 mg/kg) and a psychoactive control, using a three-way within-subject double-blind active-controlled cross-over design. Intramuscular racemic ketamine doses of 0.5 and 1.0 mg/kg produced robust effects on diagnosis-appropriate outcome scales for all these internalizing disorders, compared with psychoactive controls. These effects were most obvious at 24 h after dosing and noticeably smaller at 168 h. The magnitude of change after 1 mg/kg did not differ significantly from 0.5 mg/kg at either time point, and did not differ significantly between the internalizing disorders at 24 h. When combined with other ketamine dose-response data, we propose that ketamine may have a narrow inverted-U dose-response profile (peaking in the regions of 0.5-1.0 mg/kg) in patients with internalizing disorders. (© 2026 The Author(s). The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.) |
| References: | EClinicalMedicine. 2023 Aug 03;62:102127. (PMID: 37593223) Br Med J (Clin Res Ed). 1986 Feb 1;292(6516):344. (PMID: 3080166) J Psychopharmacol. 2024 Feb;38(2):162-167. (PMID: 38293803) J Psychopharmacol. 2025 Jan;39(1):23-28. (PMID: 39609659) Mol Psychiatry. 2020 Jul;25(7):1592-1603. (PMID: 30283029) J Psychopharmacol. 2017 Oct;31(10):1302-1305. (PMID: 28441895) Arch Gen Psychiatry. 1989 Nov;46(11):1006-11. (PMID: 2684084) Behav Res Ther. 1979;17(3):263-7. (PMID: 526242) Am J Psychiatry. 2021 May 1;178(5):383-399. (PMID: 33726522) JAMA Psychiatry. 2025 Jul 1;82(7):638-639. (PMID: 40366672) J Psychopharmacol. 2020 Mar;34(3):267-272. (PMID: 31526207) BJPsych Open. 2025 Oct 01;11(6):e230. (PMID: 41030011) Personal Neurosci. 2020 Mar 19;3:e2. (PMID: 32524063) J Neurosci. 2023 Feb 8;43(6):1038-1050. (PMID: 36596696) J Affect Disord. 2024 Apr 1;350:895-899. (PMID: 38266928) J Affect Disord. 2024 Jul 1;356:379-384. (PMID: 38537759) Br J Med Psychol. 1959;32(1):50-5. (PMID: 13638508) Expert Opin Pharmacother. 2026 Feb;27(2):123-133. (PMID: 41762703) |
| Grant Information: | Health Research Council New Zealand |
| Contributed Indexing: | Keywords: depression; dose response; generalized anxiety disorder; ketamine; obsessive‐compulsive disorder; post‐traumatic stress disorder; social anxiety disorder |
| Substance Nomenclature: | 690G0D6V8H (Ketamine) |
| Entry Date(s): | Date Created: 20260916 Date Completed: 20260916 Latest Revision: 20260918 |
| Update Code: | 20260918 |
| PubMed Central ID: | PMC13579490 |
| DOI: | 10.1002/jcph.70299 |
| PMID: | 42746802 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!